Connect Biopharma (NASDAQ: CNTB) has announced topline results from its global Phase 2 study evaluating rademikibart, its next-generation, potentially best-in-class anti-interleukin-4-receptor alpha (IL-4Rα) antibody as an add-on treatment for acute exacerbations in adult participants with chronic obstructive pulmonary disease (COPD) and type 2 inflammation.
According to Connect, rademikibart significantly reduced the rate of treatment failure compared to placebo through one month by 81% and significantly reduced the rate of new moderate to severe COPD exacerbations through one month by 85%. Rademikibart was well tolerated and significantly reduced the rate of hospitalizations or emergency department visits for new acute COPD exacerbations by 100%.
In a statement, Barry Quart, PharmD, CEO and director of Connect, commented, “Topline data from our Seabreeze STAT COPD trial for rademikibart provides overwhelming evidence of the potential benefit early treatment with rademikibart may provide to COPD patients experiencing an acute exacerbation. 2025 claims data indicate that COPD patients going to the emergency department (ED) due to an acute exacerbation generate approximately $6 billion in healthcare costs in the following 30 days due to return visits to the ED or hospital. This study demonstrated that rademikibart completely eliminated those return visits while decreasing new moderate to severe COPD exacerbations by 85% compared to placebo. These groundbreaking results provide a unique opportunity to differentiate rademikibart in COPD from all other approved biologics. We plan to engage with the FDA as soon as feasible regarding a Phase 3 registrational development program for rademikibart as add-on treatment for COPD.”
